Microsoft Brings AI to U.K. Gene-Therapy Firm
- Collaboration focused on viruses that carry healthy genes
- Microsoft to contribute cloud, machine-learning software
Photographer: Cole Burston/Bloomberg
This article is for subscribers only.
Software giant Microsoft Corp. is working with U.K. biotechnology firm Oxford Biomedica Plc on developing better ways of repairing the genes of people with life-threatening diseases.
Microsoft will use its Azure cloud and machine-learning software to develop ways to increase the productivity and purity of viruses that Oxford Biomedica makes to carry healthy genetic sequences into cells with broken and malformed genes, according to a statement Tuesday. The collaboration will last for two years and can be extended.